Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorption, Metabolism, and Excretion of [4-14C] AEF0117 in Healthy Men
NCT05554926Phase 1Completed
- Sponsor
- Aelis Farma
- Start
- Dec 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aef0117 in cannabis use disorder (CUD), sponsored by Aelis Farma. Primary endpoints: Urine excretion of [4-14C]AEF0117, Feces excretion of [4-14C]AEF0117 and 5 more. Started Dec 2022; status: completed.
02
Drugs
aef0117
03
Conditions
cannabis use disorder (CUD)
Beyond the preview
Go deeper on NCT05554926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05554926.